There is no magic cure for post treatment Lyme disease syndrome, but many patients do recover with time.

2020 ◽  
Vol 4 (3) ◽  
Author(s):  
Victoria Cairns
Keyword(s):  
Lyme Disease ◽  
Post Treatment

scholarly journals Expectancies as predictors of symptom improvement after antimicrobial therapy for persistent symptoms attributed to Lyme disease

2021 ◽  
Author(s):  
Henriët van Middendorp ◽  
Anneleen Berende ◽  
Fidel J. Vos ◽  
Hadewych H. M. ter Hofstede ◽  
Bart Jan Kullberg ◽  
...  
Keyword(s):  
Lyme Disease ◽  
Treatment Success ◽  
Symptomatic Improvement ◽  
Post Treatment ◽  
Symptom Improvement ◽  
Persistent Symptoms ◽  
Treatment Expectancies ◽  
End Of Treatment ◽  
Pre Treatment

Abstract Introduction/Objective Expectancies about symptom improvement or deterioration are reliable predictors of symptom progression and treatment outcomes (symptom resolution or symptomatic improvement) in many (non-)pharmacological studies and treatments. This study examined predictors of symptom improvement after antimicrobial therapy for persistent symptoms attributed to Lyme disease, hypothesizing particularly pre-treatment expectancies regarding symptom improvement to be predictive. Methods A predictive study was performed on pre-treatment and post-treatment individual characteristics, including expectancies, and physical and mental health–related quality of life (HRQoL) from the PLEASE-trial comparing randomized 12-weeks of doxycycline, clarithromycin-hydroxychloroquine, or placebo following 2 weeks of intravenous ceftriaxone. At end-of-treatment (14 weeks after trial start) and follow-up (52 weeks), complete data of 231 and 170 (of initial 280) patients with persistent symptoms temporally related to a history of erythema migrans or otherwise confirmed symptomatic Lyme disease, or accompanied by B. burgdorferi IgG or IgM antibodies, were examined through hierarchical regression analyses. Results In addition to pre-treatment HRQoL, pre-treatment expectancies regarding symptom improvement were consistently associated with stronger physical and mental HRQoL improvements at both end-of-treatment and follow-up (95% CI range: .09;.54, p < .01 to .27;.92, p < .001). Post-treatment expectancies regarding having received antibiotics vs. placebo was associated with more HRQoL improvement at end-of-treatment, but not at follow-up (95% CI-range 1.00;4.75, p = .003 to −7.34; −2.22, p < .001). Conclusions The present study shows that, next to pre-treatment functioning, patients’ pre-treatment and post-treatment expectancies regarding improvement of persistent symptoms attributed to Lyme disease relate to a more beneficial symptom course. Expectancies of patients may be relevant to explain and potentially improve patient outcomes (e.g., by optimized communication about treatment success). Trial registration ClinicalTrials.gov, NCT01207739 (Registration date: 23–09-2010) Key Points• As there is currently no sufficient symptom resolution or symptomatic improvement for many patients with persistent symptoms attributed to Lyme disease, it is relevant to know which factors determine symptom progression and predict heterogeneity in treatment response.• Next to pre-treatment functioning, expectancies regarding symptom improvement and having received antimicrobial study medication are associated with a more beneficial symptom course after both shorter-term and longer-term antimicrobial treatment.• Expectancies are relevant to consider in treatment studies and may be useful in clinical settings to improve symptom course and treatment outcome (e.g., by optimized communication about treatment success).

Frontotemporal Dementia Misdiagnosed for Post-Treatment Lyme Disease Syndrome or vice versa? A Treviso Dementia (TREDEM) Registry Case Report

2018 ◽  
Vol 66 (2) ◽  
pp. 445-451
Author(s):  
Maria Elena Di Battista ◽  
Carola Dell’Acqua ◽  
Luciana Baroni ◽  
Chiara Fenoglio ◽  
Daniela Galimberti ◽  
...  
Keyword(s):  
Case Report ◽  
Lyme Disease ◽  
Frontotemporal Dementia ◽  
Post Treatment

scholarly journals Development of a foundation for a case definition of post-treatment Lyme disease syndrome

2013 ◽  
Vol 17 (6) ◽  
pp. e443-e449 ◽  
Author(s):  
John N. Aucott ◽  
Lauren A. Crowder ◽  
Kathleen B. Kortte
Keyword(s):  
Lyme Disease ◽  
Case Definition ◽  
Post Treatment ◽  
Definition Of

scholarly journals Effects of intravenous ketamine in a patient with post-treatment Lyme disease syndrome

2017 ◽  
Vol Volume 10 ◽  
pp. 305-308 ◽  
Author(s):  
Ashraf Hanna ◽  
Bishoy Abraham ◽  
Andrew Hanna ◽  
Adam Smith
Keyword(s):  
Lyme Disease ◽  
Post Treatment ◽  
Intravenous Ketamine

scholarly journals Seroprevalence of Antibodies against Tick-Borne Pathogens in Czech Patients with Suspected Post-Treatment Lyme Disease Syndrome

2021 ◽  
Vol 9 (11) ◽  
pp. 2217
Author(s):  
Kristyna Sloupenska ◽  
Jana Dolezilkova ◽  
Barbora Koubkova ◽  
Beata Hutyrova ◽  
Mojmir Racansky ◽  
...  
Keyword(s):  
Lyme Disease ◽  
Significant Influence ◽  
Anaplasma Phagocytophilum ◽  
Wide Spectrum ◽  
Bartonella Henselae ◽  
Antimicrobial Treatment ◽  
Post Treatment ◽  
Babesia Microti ◽  
Serum Samples ◽  
Good Agreement

The hypothesized importance of coinfections in the pathogenesis of post-treatment Lyme disease syndrome (PTLDS) leads to the use of combined, ongoing antimicrobial treatment in many cases despite the absence of symptoms typical of the presence of infection with specific pathogens. Serum samples from 103 patients with suspected post-treatment Lyme disease syndrome were tested for the presence of antibodies to the major tick-borne pathogens Anaplasma phagocytophilum, Bartonella henselae/Bartonella quinatana, and Babesia microti. Although the presence of anti-Anaplasma antibodies was detected in 12.6% of the samples and anti-Bartonella antibodies in 9.7% of the samples, the presence of antibodies against both pathogens in the same samples or anti-Babesia antibodies in the selected group of patients could not be confirmed. However, we were able to detect autoantibodies, mostly antinuclear, in 11.6% of the patients studied. Our results are in good agreement with previously published studies showing the presence of a wide spectrum of autoantibodies in some patients with complicated forms of Lyme disease and post-treatment Lyme disease syndrome, but they do not reveal a significant influence of co-infections on the development of PTLDS in the studied group of patients.

Sign in / Sign up

Export Citation Format

Share Document